# A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock

> **NCT01144624** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 20 (actual)

## Conditions studied

- Severe Sepsis
- Septic Shock

## Interventions

- **DRUG:** AZD9773
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01144624
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01144624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01144624, "A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT01144624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*